Avalo Therapeutics Inc
(AVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 6,750 | 7,028 | 27,813 | 1,153 | 0 |
| Cost of Goods | -567 | 3,261 | 636 | N/A | N/A |
| Gross Profit | 7,317 | 3,768 | 27,178 | 1,153 | N/A |
| Operating Expenses | 22,888 | 39,407 | 13,923 | 17,233 | 11,010 |
| Operating Income | -16,137 | -35,379 | 13,890 | -16,080 | -11,010 |
| Interest Expense | 0 | 0 | 24 | 464 | 793 |
| Other Income | 147 | 55 | -30 | 73 | 1,313 |
| Pre-tax Income | -15,990 | -35,324 | 13,836 | -16,472 | -10,490 |
| Income Tax | 280 | -50 | 1,967 | N/A | N/A |
| Net Income Continuous | -16,271 | -35,274 | 11,870 | -16,472 | -10,490 |
| Net Income Discontinuous | 198 | -4,779 | N/A | N/A | N/A |
| Net Income | $-16,073 | $-40,053 | $11,870 | $-16,472 | $-10,490 |
| EPS Basic Total Ops | -800.32 | -3,429.94 | 1,200.48 | -5,345.00 | -13,462.53 |
| EPS Basic Continuous Ops | -800.32 | -3,029.78 | 1,842.88 | -5,331.65 | -13,469.63 |
| EPS Basic Discontinuous Ops | 0.00 | -400.16 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -4,030.18 | -3,429.94 | 1,200.48 | -5,345.00 | -13,462.53 |
| EPS Diluted Continuous Ops | -4,058.77 | -3,029.78 | 1,809.00 | -5,331.65 | -13,469.63 |
| EPS Diluted Discontinuous Ops | 28.58 | -400.16 | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -857.49 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-10,698 | $-28,661 | $14,453 | $-16,053 | $-10,986 |